The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•21 April 2026•

1 min read

Enlivex Receives Danish Approval for Phase 2b Osteoarthritis Trial

Fortified uniQure building, fences, caution tape, security cameras. FDA buildings, US flags, justice symbols. Charts on tablets and papers.

Key Facts

1Enlivex received approval from the Danish Medicines Agency (DKMA) to initiate Phase 2b trials for Allocetra.

2The trial targets patients with age-related primary moderate-to-severe knee osteoarthritis.

Enlivex Therapeutics has announced that it received approval from the Danish Medicines Agency (DKMA) to initiate a Phase 2b clinical trial for its drug candidate, Allocetra. The trial is specifically designed to target patients suffering from age-related primary moderate-to-severe knee osteoarthritis. This regulatory milestone follows a previous clearance from the US Food and Drug Administration (FDA) to conduct the study within the United States. By securing approval in Denmark, the company expands its clinical footprint into the European market, allowing for broader patient enrollment. This procedural advancement is a critical step in the long-term development cycle of Allocetra. Analysts view this expansion as a positive signal for the company's clinical pipeline and regulatory strategy.